ID

43983

Description

Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00663429

Lien

https://clinicaltrials.gov/show/NCT00663429

Mots-clés

Versions (2)
  1. 04/07/2017 04/07/2017 -
  2. 20/09/2021 20/09/2021 -
Téléchargé le

20 septembre 2021

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Neuroendocrine Carcinoma NCT00663429

Anglais

Eligibility Neuroendocrine Carcinoma NCT00663429

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. subject was enrolled in protocol no. cp-106 and successfully completed 12 treatment cycles.
Description

ID.1

Type de données

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0008976
2. subject must have been classified as a responder at the time of completion of protocol no. cp-106 [i.e., sd or better per recist committee criteria or stable symptoms or better (defined as an average daily frequency of bowel movements, flushing episodes and/or wheezing episodes that is the same as or less than the average daily frequency of bowel movements, flushing episodes and/or wheezing episodes recorded during the 14-day screening period prior to enrollment in protocol no. cp-106)].
Description

ID.2

Type de données

boolean

Alias
UMLS CUI [1,1]
C0012240
UMLS CUI [1,2]
C0919876
3. subject must understand and voluntarily sign the informed consent document.
Description

ID.3

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
4. subject must have adequate organ function defined as follows: absolute granulocyte count (agc) >1,500/mm3, hemoglobin >8 g/dl, platelets >100,000/mm3, serum bilirubin <1.5 x upper limit of normal (uln), serum creatinine <1.5 mg/dl, sgot ≤grade 1 per nci ctcae, sgpt ≤grade 1 per nci ctcae.
Description

ID.4

Type de données

boolean

Alias
UMLS CUI [1]
C0678852
5. women of child bearing potential (wcbp) must have a negative serum or urine pregnancy test. in addition sexually active wcbp must agree to use adequate contraceptive methods (oral, injectable or implantable hormonal contraceptive; tubal ligation; intra-uterine devices; barrier contraceptive with spermicide; or vasectomized partner).
Description

ID.5

Type de données

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0009862
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. subject who was enrolled in protocol no. cp-106 and who did not successfully complete 12 treatment cycles.
Description

ID.6

Type de données

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0008976
2. if wcbp, pregnant, lactating or not using adequate contraception.
Description

ID.7

Type de données

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
UMLS CUI [1,3]
C0009862
3. clinically relevant active infection or serious co-morbid medical conditions that are uncontrolled or whose control may be jeopardized by atiprimod treatment.
Description

ID.8

Type de données

boolean

Alias
UMLS CUI [1,1]
C3714514
UMLS CUI [1,2]
C0012634
4. psychiatric disorders rendering subjects incapable of complying with the requirements of the protocol.
Description

ID.9

Type de données

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C1321605
5. any condition which, in the opinion of the investigator, places the subject at unacceptable risk if he/she were to participate in the study.
Description

ID.10

Type de données

boolean

Alias
UMLS CUI [1]
C0012634
6. as atiprimod is a potent inhibitor of cyp2d6, the use of drugs that are substrates of cyp2d6 (e.g. beta blockers, antidepressants, and antipsychotic;) will not be allowed while on study.
Description

ID.11

Type de données

boolean

Alias
UMLS CUI [1,1]
C0057223
UMLS CUI [1,2]
C1579206
Retour au début de la page

Similar models

Eligibility Neuroendocrine Carcinoma NCT00663429

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
1. subject was enrolled in protocol no. cp-106 and successfully completed 12 treatment cycles.
boolean
C0087111 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
ID.2
Item
2. subject must have been classified as a responder at the time of completion of protocol no. cp-106 [i.e., sd or better per recist committee criteria or stable symptoms or better (defined as an average daily frequency of bowel movements, flushing episodes and/or wheezing episodes that is the same as or less than the average daily frequency of bowel movements, flushing episodes and/or wheezing episodes recorded during the 14-day screening period prior to enrollment in protocol no. cp-106)].
boolean
C0012240 (UMLS CUI [1,1])
C0919876 (UMLS CUI [1,2])
ID.3
Item
3. subject must understand and voluntarily sign the informed consent document.
boolean
C0021430 (UMLS CUI [1])
ID.4
Item
4. subject must have adequate organ function defined as follows: absolute granulocyte count (agc) >1,500/mm3, hemoglobin >8 g/dl, platelets >100,000/mm3, serum bilirubin <1.5 x upper limit of normal (uln), serum creatinine <1.5 mg/dl, sgot ≤grade 1 per nci ctcae, sgpt ≤grade 1 per nci ctcae.
boolean
C0678852 (UMLS CUI [1])
ID.5
Item
5. women of child bearing potential (wcbp) must have a negative serum or urine pregnancy test. in addition sexually active wcbp must agree to use adequate contraceptive methods (oral, injectable or implantable hormonal contraceptive; tubal ligation; intra-uterine devices; barrier contraceptive with spermicide; or vasectomized partner).
boolean
C0032961 (UMLS CUI [1,1])
C0009862 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
ID.6
Item
1. subject who was enrolled in protocol no. cp-106 and who did not successfully complete 12 treatment cycles.
boolean
C0087111 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
ID.7
Item
2. if wcbp, pregnant, lactating or not using adequate contraception.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C0009862 (UMLS CUI [1,3])
ID.8
Item
3. clinically relevant active infection or serious co-morbid medical conditions that are uncontrolled or whose control may be jeopardized by atiprimod treatment.
boolean
C3714514 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
ID.9
Item
4. psychiatric disorders rendering subjects incapable of complying with the requirements of the protocol.
boolean
C0004936 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
ID.10
Item
5. any condition which, in the opinion of the investigator, places the subject at unacceptable risk if he/she were to participate in the study.
boolean
C0012634 (UMLS CUI [1])
ID.11
Item
6. as atiprimod is a potent inhibitor of cyp2d6, the use of drugs that are substrates of cyp2d6 (e.g. beta blockers, antidepressants, and antipsychotic;) will not be allowed while on study.
boolean
C0057223 (UMLS CUI [1,1])
C1579206 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial